Welcome to LookChem.com Sign In|Join Free

Hubei Vanz Pharm Co.,Ltd

Diamond Supplier Enterprise Certification

Diamond
Supplier
6th
years
Home>>Products>>cas 163222-33-1 99% Ezetimibe powder

Product Certification&
Enterprise Certification

More Detail

Hubei Vanz Pharm Co.,Ltd

Country: China (Mainland)

Business Type:Trading Company

Ms.Chelsea gao

Tel: 86-27-84492310

Ms.Bella Li

Tel: 008618986076206

Ms.Chelsea Gao

Tel: +86 27 84492310

Ms.Wendy

Tel: WhatsApp +8615927784577

Ms.Mirriam

Tel: +8618071739296

Mobile: +8615207100586

Tel: 86-27-84492310

Fax: 86-27-84402310

URL: http://www.vanzpharm.com/en/index.html

Province/state: Hubei

City: JIAYU

Street: FANHU INDUSTRY PARK

MaxCard:


    x
  • Ms.Bella Li
  • Ms.Chelsea Gao
Contact Suppliers

cas 163222-33-1 99% Ezetimibe powder

CAS NO.163222-33-1

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,
Contact Supplier

Product Details

Keywords

  • Ezetimibe
  • Ezetimibe powder
  • 99% Ezetimibe

Quick Details

  • ProName: cas 163222-33-1 99% Ezetimibe powd...
  • CasNo: 163222-33-1
  • Molecular Formula: C15H22O5
  • Appearance: white
  • Application: ?Ezetimibe is ananti-hyperlipidemic dr...
  • DeliveryTime: 7-10 days
  • PackAge: drum
  • Port: Shanghai/Wuhan
  • ProductionCapacity: 1000 Kilogram/Day
  • Purity: 99
  • Storage: room
  • LimitNum: 1 Kilogram

Superiority

 cas  163222-33-1  99%   Ezetimibe powder

Product Name: Ezetimibe
CAS: 163222-33-1
MF: C24H21F2NO3
MW: 409.43
EINECS: 682-606-0

 

Details

cas  163222-33-1  99%   Ezetimibe powder 

 Ezetimibe is ananti-hyperlipidemic drug used for lowering the plasma cholesterol levels.
  

 It is indicated as an adjunctive therapy to diet for the reduction of high-level total-C, LDL-C, and ApoB in patients suffering primary (heterozygous familial and non-familial) hypercholesterolemia. It is also used in combination therapy with HMG-CoA reductase inhibitors.Ezetimibe does not inhibit the cholesterol synthesis in the liver, or increase bile acid excretion.It takes effect throughacting at the brush border of the small intestine and inhibiting the absorption of cholesterol, further leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of blood cholesterol. For use as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.